.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech want to detail on the Nasdaq under the symbol "BIOA," according to papers submitted along with the Securities and Swap Commission. The provider has not openly discussed an expected financial volume for the offering.The clinical-stage company boasts lead applicant azelaprag, an orally delivered tiny molecule slated to enter stage 2 testing in combination along with semaglutide-- offered by Novo Nordisk under trademark name Wegovy for weight management-- in the very first fifty percent of following year. Semaglutide is actually additionally offered as Ozempic and also Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is developed to blend effectively with GLP-1 medications, boosting fat loss while protecting muscle mass. The investigational medicine was actually found to become well-tolerated one of 265 people across 8 phase 1 tests, depending on to BioAge.Previously, BioAge gathered the help of Lilly to operate a trial blending azelaprag with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro and also Zepbound for effective weight loss. The companions are currently conducting a period 2 trial of azelaprag as well as tirzepatide, with topline end results assumed in the 3rd one-fourth of 2025.The biotech is additionally preparing a blood insulin level of sensitivity proof-of-concept trial examining azelaprag as a monotherapy in the very first fifty percent of upcoming year to assist prospective evidence expansion. Additionally, the firm considers to ask the FDA for approval in the 2nd half of 2025 to release individual testing for an NLRP3 inhibitor targeting metabolic ailments and also neuroinflammation.BioAge's expected move to everyone market follows a small uptick in considered biotech IPOs coming from Bicara Therapies and also Zenas Biopharma. Zooming out, the latest IPO yard is a "blended picture," with high-quality business still debuting on the public markets, merely in decreased varieties, depending on to PitchBook.